Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 6Neuroendocrine Tumors 5Neoplasm Metastasis 3Carcinoma, Renal Cell 3Tuberous Sclerosis 2Triple Negative Breast Neoplasms 2Recurrence 2Glioma 2Endometrial Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Vascular Malformations 1Unilateral Breast Neoplasms 1Thymus Neoplasms 1Seizures 1Sarcoma, Kaposi 1Sarcoma 1Nevus 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Lymphangioma 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Kidney Neoplasms 1Hemangioma 1Hemangioendothelioma 1Hamartoma Syndrome, Multiple 1

Interventions

Cannabidiol 3Everolimus 2radiprodil 1Solutions 1Propranolol 1Phlebotomy 1Genetic Testing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Tuberous Sclerosis × Everolimus × 90 days × Clear all
NCT02962414 2026-04-02

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Novartis

Phase 3 Active not recruiting
206 enrolled

Seizures, Tuberous Sclerosis

NCT05252585 2026-04-02

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Novartis

Phase 4 Active not recruiting
4 enrolled

Tuberous Sclerosis, Angiomyolipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡